免疫療法薬の世界市場：薬剤タイプ別、適応症別、投与経路別、エンドユーザー別、地域別、機会、予測、2018年～2032年

世界の免疫療法薬の市場規模は、2025年～2032年の予測期間中に11.11%のCAGRで拡大し、2024年の2,513億米ドルから2032年には5,837億4,000万米ドルに成長すると予測されています。世界の免疫療法薬市場は、自己免疫疾患の予防と治療に対するニーズの高まりによって急速に拡大しています。市場成長の原動力となっているのは、がん患者の増加、政府の強力な予防接種プログラム、一般市民の意識の高まりです。WHO、Gavi、ユニセフのような政府や組織は、特に発展途上国において大規模な予防接種キャンペーンに積極的に資金を提供し、支援しています。バイオテクノロジー大手は、大きな成果を生み出すことができるよう結集しつつあります。

さらに、mRNAワクチンや組み換えワクチンなど、ワクチン技術の進歩が開発と生産を加速させています。製薬会社やバイオテクノロジー企業による研究開発投資の増加は、HIVやがんなどの疾患に対する革新的な免疫療法薬の開発につながっています。有利な規制政策と医療費の増加が市場拡大をさらに後押ししています。高齢者人口の増加、新興国におけるヘルスケア・インフラの整備、世界のワクチン接種率の拡大は、市場の長期的な成長を維持すると予想されます。例えば、2023年5月、Precigen, Inc.は、FDAが治験薬（IND）申請を承認した後、第2相調査の開始を発表しました。ファースト・イン・クラスのPRGN-2009 Off-the-Shelf（OTS）AdenoVerse免疫療法は、この研究でペムブロリズマブとともに評価されます。転移性または再発性の子宮頸がん患者が主な対象です。

当レポートでは、世界の免疫療法薬市場について調査し、市場の概要とともに、薬剤タイプ別、適応症別、投与経路別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の免疫療法薬市場の見通し、2018年～2032年

• 市場規模の分析と予測
• 市場シェア分析と予測
• 市場マップ分析、2024年
  • 薬剤タイプ別
  • 適応症別
  • 投与経路別
  • エンドユーザー別
  • 地域別

第5章 北米の免疫療法薬市場の見通し、2018年～2032年

第6章 欧州の免疫療法薬市場の見通し、2018年～2032年

第7章 アジア太平洋の免疫療法薬市場の見通し、2018年～2032年

第8章 南米の免疫療法薬市場の見通し、2018年～2032年

第9章 中東・アフリカの免疫療法薬市場の見通し、2018年～2032年

第10章 需要供給分析

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

第13章 PESTLE分析

第14章 価格分析

第15章 市場力学

第16章 市場の動向と発展

第17章 規制枠組みとイノベーション

第18章 特許の情勢

第19章 ケーススタディ

第20章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche Ltd
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Novartis AG
  • Eli Lilly and Company
  • Johnson & Johnson Services, Inc.
  • AstraZeneca plc

第21章 戦略的提言

第22章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 3. Global Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 4. Global Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 5. Global Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 6. Global Immunotherapy Drugs Market Share (%), By Region, 2018-2032F
• Figure 7. North America Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 8. North America Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 9. North America Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 10. North America Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 11. North America Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 12. North America Immunotherapy Drugs Market Share (%), By Country, 2018-2032F
• Figure 13. United States Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 14. United States Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 15. United States Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 16. United States Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 17. United States Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 18. Canada Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 19. Canada Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 20. Canada Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 21. Canada Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 22. Canada Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 23. Mexico Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 24. Mexico Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 25. Mexico Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 26. Mexico Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 27. Mexico Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 28. Europe Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Europe Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 30. Europe Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 31. Europe Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 32. Europe Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 33. Europe Immunotherapy Drugs Market Share (%), By Country, 2018-2032F
• Figure 34. Germany Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 35. Germany Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 36. Germany Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 37. Germany Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 38. Germany Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 39. France Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 40. France Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 41. France Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 42. France Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 43. France Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 44. Italy Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 45. Italy Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 46. Italy Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 47. Italy Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 48. Italy Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 49. United Kingdom Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 50. United Kingdom Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 51. United Kingdom Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 52. United Kingdom Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 53. United Kingdom Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 54. Russia Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 55. Russia Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 56. Russia Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 57. Russia Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 58. Russia Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 59. Netherlands Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 60. Netherlands Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 61. Netherlands Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 62. Netherlands Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 63. Netherlands Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 64. Spain Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 65. Spain Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 66. Spain Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 67. Spain Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 68. Spain Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 69. Turkey Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Turkey Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 71. Turkey Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 72. Turkey Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 73. Turkey Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 74. Poland Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 75. Poland Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 76. Poland Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 77. Poland Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 78. Poland Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 79. South America Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 80. South America Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 81. South America Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 82. South America Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 83. South America Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 84. South America Immunotherapy Drugs Market Share (%), By Country, 2018-2032F
• Figure 85. Brazil Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 86. Brazil Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 87. Brazil Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 88. Brazil Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 89. Brazil Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 90. Argentina Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 91. Argentina Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 92. Argentina Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 93. Argentina Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 94. Argentina Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 95. Asia-Pacific Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 96. Asia-Pacific Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 97. Asia-Pacific Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 98. Asia-Pacific Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 99. Asia-Pacific Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 100. Asia-Pacific Immunotherapy Drugs Market Share (%), By Country, 2018-2032F
• Figure 101. India Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 102. India Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 103. India Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 104. India Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 105. India Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 106. China Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 107. China Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 108. China Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 109. China Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 110. China Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 111. Japan Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 112. Japan Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 113. Japan Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 114. Japan Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 115. Japan Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 116. Australia Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 117. Australia Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 118. Australia Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 119. Australia Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 120. Australia Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 121. Vietnam Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 122. Vietnam Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 123. Vietnam Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 124. Vietnam Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 125. Vietnam Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 126. South Korea Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 127. South Korea Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 128. South Korea Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 129. South Korea Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 130. South Korea Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 131. Indonesia Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 132. Indonesia Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 133. Indonesia Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 134. Indonesia Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 135. Indonesia Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 136. Philippines Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 137. Philippines Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 138. Philippines Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 139. Philippines Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 140. Philippines Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 141. Middle East & Africa Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 142. Middle East & Africa Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 143. Middle East & Africa Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 144. Middle East & Africa Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 145. Middle East & Africa Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 146. Middle East & Africa Immunotherapy Drugs Market Share (%), By Country, 2018-2032F
• Figure 147. Saudi Arabia Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 148. Saudi Arabia Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 149. Saudi Arabia Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 150. Saudi Arabia Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 151. Saudi Arabia Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 152. UAE Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 153. UAE Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 154. UAE Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 155. UAE Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 156. UAE Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 157. South Africa Immunotherapy Drugs Market, By Value, In USD Billion, 2018-2032F
• Figure 158. South Africa Immunotherapy Drugs Market Share (%), By Drug Type, 2018-2032F
• Figure 159. South Africa Immunotherapy Drugs Market Share (%), By Indication, 2018-2032F
• Figure 160. South Africa Immunotherapy Drugs Market Share (%), By Route of Administration, 2018-2032F
• Figure 161. South Africa Immunotherapy Drugs Market Share (%), By End-user, 2018-2032F
• Figure 162. By Drug Type Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 163. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 164. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 165. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 166. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global immunotherapy drugs market is projected to witness a CAGR of 11.11% during the forecast period 2025-2032, growing from USD 251.30 billion in 2024 to USD 583.74 billion in 2032. The global immunotherapy drug market is expanding rapidly, driven by the increasing need to prevent and cure autoimmune diseases. The market's growth is fueled by rising cases of cancer, strong government immunization programs, and increasing public awareness. Governments and organizations like WHO, Gavi, and UNICEF are actively funding and supporting large-scale vaccination campaigns, especially in developing countries. Biotechnology giants are coming together to be able to produce big results. Additionally, advancements in vaccine technology, such as mRNA and recombinant vaccines, are accelerating development and production. Increased R&D investments from pharmaceutical companies and biotech firms are leading to innovative immunotherapy drugs for diseases such as HIV, and cancer. Favorable regulatory policies and growing healthcare expenditures further support market expansion. The increasing geriatric population, rising healthcare infrastructure in emerging economies, and expanding global vaccination coverage are expected to sustain the market's long-term growth. For instance, in May 2023, Precigen, Inc. announced the launch of a Phase 2 research after the FDA approved an investigatory new drug (IND) application. The first-in-class PRGN-2009 Off-the-Shelf (OTS) AdenoVerse immunotherapy will be assessed in this study in conjunction with pembrolizumab. Patients with metastatic or recurring cervical cancer are of main focus.

Strategic Collaborations and Mergers Boosts Market Demand

The immunotherapy market is witnessing an increasing number of strategic collaborations, partnerships, and mergers as pharmaceutical companies aim to strengthen their product pipelines and accelerate drug development. Leading companies are forming alliances with biotech firms, research institutions, and healthcare organizations to leverage expertise, share resources, and gain access to innovative technologies. For example, to develop a novel late-stage clinical immuno-oncology pipeline of treatments to overcome cancer immunotherapy resistance, CohBar, Inc. and Morphogenesis, Inc. signed a definitive merger agreement in May 2023. Similarly, MediLink Therapeutics and BioNTech announced a multi-target TMALIN ADC technology platform license deal in May 2024, strengthening their strategic alliance on a global scale. Such collaborations facilitate the rapid development and commercialization of novel immunotherapies by combining expertise in different therapeutic areas. Licensing agreements and joint ventures also play a crucial role in overcoming regulatory challenges and market entry barriers. Moreover, partnerships with universities and research labs enable firms to stay ahead in emerging fields like personalized cancer immunotherapy. These strategic moves are significantly shaping the competitive landscape of the immunotherapy market.

Advancements in Biotechnological Sector Supports Market Expansion

Immunotherapy is being revolutionized by biotechnology, which makes it possible to create more individualized, accurate, and efficient treatments. Recent developments in cell-based therapy, genetic engineering, and the creation of monoclonal antibodies have greatly enhanced patient outcomes. CAR-T cell therapy, which includes altering a patient's immune cells to identify and combat cancer cells, is among the most revolutionary developments. Additionally, by stopping tumor cells from eluding immune responses, checkpoint inhibitors such as PD-1 and CTLA-4 blockers have demonstrated impressive efficacy in treating a variety of malignancies. Furthermore, the creation of next-generation immunotherapies is accelerated by bioinformatics and AI-driven drug discovery developments. Additionally, scientists are developing bispecific antibodies that can target several cancer pathways at once, improving the effectiveness of treatment. The administration of immunotherapy is being further optimized by the incorporation of nanotechnology into medication delivery devices. These continuous technological breakthroughs are expanding the potential of immunotherapy, making it one of the fastest-growing segments in the pharmaceutical industry. For instance, A Phase I/II trial (NCT03665285) to assess the safety and tolerability of NC318 as a possible treatment for advanced or metastatic solid cancers was announced by NextCure, Inc. in September 2023. Evaluations for diseases such as ovarian cancer, non-small cell lung cancer, and head and neck squamous cell carcinoma are part of the experiment.

Cancer Accounting for a Significant Share of the Market

One of the main factors propelling the market for immunotherapy medications is the rising incidence of autoimmune disorders and cancer worldwide. For example, according to a report by the American Cancer Society published in 2025, new cancer cases are expected in the United States are 2,041,910, which is an alarmingly high figure and should be addressed. The most common cancers are breast, lung, colon and rectum, and prostate cancers. In more advanced cases, traditional treatments like radiation and chemotherapy can have little efficacy and serious adverse effects. A promising substitute is immunotherapy, which uses the body's immune system to combat illnesses. In a similar vein, environmental influences, lifestyle modifications, and genetic predispositions are contributing to an increase in autoimmune disorders like psoriasis, multiple sclerosis, and rheumatoid arthritis. Monoclonal antibodies, checkpoint inhibitors, and cytokine-based therapies are examples of immunotherapies that offer focused and durable relief. The increasing patient pool and advancements in diagnostic techniques drive the demand for immunotherapy drugs, making them an essential component of modern treatment strategies.

North America Holds Major Market Share in the Market

North America holds the greatest market share in the global market for immunotherapy drugs because of its strong healthcare system, cutting-edge medical research, and high patient awareness. Many pharmaceutical and biotechnology firms specializing in cancer vaccine research and development are based in the United States. Significant public and corporate investments in the area support steady advancements in vaccine development. Furthermore, North America has a well-established healthcare system and a comparatively quicker clearance process for new medications, which makes advanced treatments and vaccinations more widely available to the populace. Additionally, the existence of cancer vaccine reimbursement programs guarantees that patients can afford their therapies. Furthermore, the market in North America is being supported by rising healthcare costs and growing awareness of the benefits of vaccinations for cancer prevention. Leading pharmaceutical firms like Merck and GlaxoSmithKline help propel product research and commercialization, which in turn helps the market expansion for drugs and vaccines. For instance, the presentation of first comprehensive results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck & Co. Inc.'s anti-PD-1 therapy, in patients with resected high-risk melanoma (stage III/IV) was made by Moderna, Inc., a biotechnology company that is at the forefront of messenger RNA (mRNA) therapeutics and vaccines. Adjuvant treatment with mRNA-4157 (V940) in conjunction with KEYTRUDA improved recurrence-free survival (RFS) in the entire intention-to-treat population in a statistically significant and clinically meaningful way. It also decreased the risk of recurrence or death by 44% when compared to KEYTRUDA alone. North America maintains its position as the leading area in the worldwide market due to its comprehensive healthcare regulations and emphasis on cancer prevention.

Future Market Scenario (2025-2032F)

One of the main factors contributing to the anticipated growth of the immunotherapy drugs market is the increasing demand for treatment options to ensure patient safety by delivering the right quality of drug or any other such chemical product. Not only that, but the rising population and cases of cancer are also a factor that will always propel market growth in the future. Given that technology is advancing, we can expect cutting-edge technology in the area also. Players in this market are expanding at an un-paralleled rate, introducing cost-effective and efficient technologies. For instance, OncoC4, Inc., a clinical-stage biopharmaceutical firm committed to the discovery and development of innovative biologicals for cancer therapy among patients, partnered with BioNTech SE in March 2023.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of immunotherapy drugs and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, in December 2023, F. Hoffmann-La Roche completed the acquisition of Telavant Holdings, Inc., which is owned by Roivant Sciences and Pfizer. It was anticipated that this agreement will enable Roche to create RVT-3101, a novel treatment for inflammatory bowel conditions like Crohn's disease and ulcerative colitis. The acquisition was a part of Roche's plan to increase its emphasis on gastrointestinal health and provide patients with these disorders with cutting-edge therapies.

Also, in April 2024, Boehringer Ingelheim and 3T Biosciences entered into a second partnership to develop next-generation cancer immunotherapies.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Immunotherapy Drugs Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Drug Type
    • 4.2.1.1. Monoclonal Antibodies
    • 4.2.1.2. Vaccines
    • 4.2.1.3. Immunomodulators
  • 4.2.2. By Indication
    • 4.2.2.1. Cancer
    • 4.2.2.2. Infectious Diseases
    • 4.2.2.3. Autoimmune Diseases
    • 4.2.2.4. Neurological Disorder
    • 4.2.2.5. Others
  • 4.2.3. By Route of Administration
    • 4.2.3.1. Intravenous
    • 4.2.3.2. Intramuscular
    • 4.2.3.3. Oral
    • 4.2.3.4. Subcutaneous
    • 4.2.3.5. Other
  • 4.2.4. By Distribution Channel
    • 4.2.4.1. Hospital Pharmacies
    • 4.2.4.2. Retail Pharmacies
    • 4.2.4.3. Online Pharmacies
    • 4.2.4.4. Others
  • 4.2.5. By Region
    • 4.2.5.1. North America
    • 4.2.5.2. Europe
    • 4.2.5.3. Asia-Pacific
    • 4.2.5.4. South America
    • 4.2.5.5. Middle East and Africa
  • 4.2.6. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Drug Type
  • 4.3.2. By Indication
  • 4.3.3. By Route of Administration
  • 4.3.4. By End-user
  • 4.3.5. By Region

5. North America Immunotherapy Drugs Market Outlook, 2018-2032F*

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Drug Type
    • 5.2.1.1. Monoclonal Antibodies
    • 5.2.1.2. Vaccines
    • 5.2.1.3. Immunomodulators
  • 5.2.2. By Indication
    • 5.2.2.1. Cancer
    • 5.2.2.2. Infectious Diseases
    • 5.2.2.3. Autoimmune Diseases
    • 5.2.2.4. Neurological Disorder
    • 5.2.2.5. Others
  • 5.2.3. By Route of Administration
    • 5.2.3.1. Intravenous
    • 5.2.3.2. Intramuscular
    • 5.2.3.3. Oral
    • 5.2.3.4. Subcutaneous
    • 5.2.3.5. Other
  • 5.2.4. By Distribution Channel
    • 5.2.4.1. Hospital Pharmacies
    • 5.2.4.2. Retail Pharmacies
    • 5.2.4.3. Online Pharmacies
    • 5.2.4.4. Others
  • 5.2.5. By Country Share
    • 5.2.5.1. United States
    • 5.2.5.2. Canada
    • 5.2.5.3. Mexico
• 5.3. Country Market Assessment
  • 5.3.1. United States Immunotherapy Drugs Market Outlook, 2018-2032F*
    • 5.3.1.1. Market Size Analysis & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share Analysis & Forecast
      • 5.3.1.2.1. By Drug Type
        • 5.3.1.2.1.1. Monoclonal Antibodies
        • 5.3.1.2.1.2. Vaccines
        • 5.3.1.2.1.3. Immunomodulators
      • 5.3.1.2.2. By Indication
        • 5.3.1.2.2.1. Cancer
        • 5.3.1.2.2.2. Infectious Diseases
        • 5.3.1.2.2.3. Autoimmune Diseases
        • 5.3.1.2.2.4. Neurological Disorder
        • 5.3.1.2.2.5. Others
      • 5.3.1.2.3. By Route of Administration
        • 5.3.1.2.3.1. Intravenous
        • 5.3.1.2.3.2. Intramuscular
        • 5.3.1.2.3.3. Oral
        • 5.3.1.2.3.4. Subcutaneous
        • 5.3.1.2.3.5. Other
      • 5.3.1.2.4. By Distribution Channel
        • 5.3.1.2.4.1. Hospital Pharmacies
        • 5.3.1.2.4.2. Retail Pharmacies
        • 5.3.1.2.4.3. Online Pharmacies
        • 5.3.1.2.4.4. Others
  • 5.3.2. Canada
  • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Immunotherapy Drugs Market Outlook, 2018-2032F

• 6.1. Germany
• 6.2. France
• 6.3. Italy
• 6.4. United Kingdom
• 6.5. Russia
• 6.6. Netherlands
• 6.7. Spain
• 6.8. Poland

7. Asia-Pacific Immunotherapy Drugs Market Outlook, 2018-2032F

• 7.1. India
• 7.2. China
• 7.3. Japan
• 7.4. Australia
• 7.5. Vietnam
• 7.6. South Korea
• 7.7. Indonesia
• 7.8. Philippines

8. South America Immunotherapy Drugs Market Outlook, 2018-2032F

• 8.1. Brazil
• 8.2. Argentina

9. Middle East and Africa Immunotherapy Drugs Market Outlook, 2018-2032F

• 9.1. Saudi Arabia
• 9.2. UAE
• 9.3. South Africa
• 9.4. Israel

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

• 15.1. Market Drivers
• 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Framework and Innovation

• 17.1. Regulatory Approvals
• 17.2. Clinical Trials

18. Patent Landscape

19. Case Studies

20. Competitive Landscape

• 20.1. Competition Matrix of Top 5 Market Leaders
• 20.2. SWOT Analysis for Top 5 Players
• 20.3. Key Players Landscape for Top 10 Market Players
  • 20.3.1. Merck & Co., Inc.
    • 20.3.1.1. Company Details
    • 20.3.1.2. Key Management Personnel
    • 20.3.1.3. Products and Services
    • 20.3.1.4. Financials (As Reported)
    • 20.3.1.5. Key Market Focus and Geographical Presence
    • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisitions
  • 20.3.2. GlaxoSmithKline plc
  • 20.3.3. F. Hoffmann-La Roche Ltd
  • 20.3.4. AbbVie Inc.
  • 20.3.5. Amgen Inc.
  • 20.3.6. Bristol-Myers Squibb Company
  • 20.3.7. Novartis AG
  • 20.3.8. Eli Lilly and Company
  • 20.3.9. Johnson & Johnson Services, Inc.
  • 20.3.10. AstraZeneca plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer